AlgeriaTuberculosis profile
Population  2016 41 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.1 (2–4.5) 7.7 (4.9–11)
Mortality (HIV+TB only) 0.035 (0.017–0.059) 0.09 (0.04–0.15)
Incidence  (includes HIV+TB) 29 (22–36) 70 (54–89)
Incidence (HIV+TB only) 0.17 (0.09–0.28) 0.42 (0.22–0.69)
Incidence (MDR/RR-TB)** 0.46 (0.14–0.78) 1.1 (0.34–1.9)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 1.9 (1.4–2.4) 8.9 (6.6–11) 11 (8.1–13)
Males 2 (1.5–2.5) 16 (12–20) 18 (13–22)
Total 3.9 (2.9–4.9) 25 (18–31) 29 (22–36)
TB case notifications, 2016  
Total cases notified 22 998
Total new and relapse 22 801
          - % tested with rapid diagnostics at time of diagnosis <1%
          - % with known HIV status  
          - % pulmonary 37%
          - % bacteriologically confirmed among pulmonary 86%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.11 (0.07–0.17)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  160
(24–300)
Estimated % of TB cases with MDR/RR-TB 1.4% (0.33–2.5) 9.1% (0–29)  
% notified tested for rifampicin resistance <1% 12% 89
MDR/RR-TB cases tested for resistance to second-line drugs   13
Laboratory-confirmed cases MDR/RR-TB: 31, XDR-TB: 5
Patients started on treatment **** MDR/RR-TB: 75, XDR-TB: 5
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 90% 7 082
Previously treated cases, excluding relapse, registered in 2015 82% 482
HIV-positive TB cases registered in 2015    
MDR/RR-TB cases started on second-line treatment in 2014    
XDR-TB cases started on second-line treatment in 2014    
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2017-11-17 Data: www.who.int/tb/data